BOLD Capital Partners

VCMatch tracks BOLD Capital Partners as an investor focused on AI/ML, Biotech, and Healthtech companies, Pre-Seed and Seed rounds, and United States, California, and Boston markets. Upload your deck to compare your startup against the full private matching profile.

Check Size

Not specified

Stages

Pre-Seed, Seed, Series A, Series B, Growth, Late Stage

Focus Areas

AI/ML, Biotech, Healthtech

Geography

United States, California, and Boston

Investment Thesis

BOLD seeks entrepreneurs and companies with a fierce vision for a brighter tomorrow. They identify emerging science and technologies that will disrupt and democratize massive markets, creating innovative solutions to humanity’s greatest challenges. The firm believes that convergence of the physical, digital, virtual, and biological world—driven by exponential technological advances—will enable transformative business creation and uplift humanity.

Is BOLD Capital Partners right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

BOLD Capital Partners is most relevant for founders raising Pre-Seed, Seed, and Series A rounds in AI/ML, Biotech, Healthtech, and Digital Health, especially across United States, California, and Boston.

Focus statement

BOLD invests in two primary transformative areas: (1) Health & Life Sciences, focusing on longevity, patient-enabled health management, and synthetic biology; and (2) Deep Tech & Productivity, investing in exponential technologies like AI, Blockchain, Sensors, VR, and 3D printing that democratize access and dramatically lower costs.

Value Add

Focus on convergence of physical, digital, virtual, and biological worlds driven by exponential technology
Emphasis on democratizing massive markets and creating access for broader populations
Dedicated longevity fund (BOLD Longevity Growth) with specialized expertise in aging and health optimization
Team composition includes entrepreneurs, engineers, physicists, biologists, doctors with diverse expertise
Track record of exits including IPOs (Insilico Medicine on Hong Kong Exchange, Deep Longevity) and strategic M&A